BOD SCIENCE LIMITED - Announcements

Market Cap $4.256M Add to my watchlist

Healthcare

Bod Science Limited is an Australia-based cannabis focused drug development and product... Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for patients and consumers. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company operates through three segments: medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Announcements

Filter Results

All Price Sensitive Only

BOD	Further delay in lodgement of App 4D and Half Year Report		29/04/24	234.8KB	Share
BOD	Entry into Deed of Company Arrangement	PRICE SENSITIVE	26/04/24	240.67KB	Share
BOD	Quarterly Activities Report / Appendix 4C	PRICE SENSITIVE	24/04/24	1.17MB	Share
BOD	Change of Principal Place of Business		12/04/24	229.58KB	Share
BOD	Convening of Second Meeting of Creditors		28/03/24	321.53KB	Share
BOD	Further delay in lodgement of App.4D and Half Year Report		25/03/24	271.77KB	Share
BOD	Delay in lodgement of Appendix 4D and Half Year Report		29/02/24	271.9KB	Share
BOD	Change of Director's Interest Notice		08/02/24	126.58KB	Share
BOD	Notification of cessation of securities - BOD		08/02/24	12.73KB	Share
BOD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	643.56KB	Share
BOD	Extension of Convening Period for 2nd Meeting of Creditors	PRICE SENSITIVE	15/12/23	587.14KB	Share
BOD	Medicinal cannabis supply agreement with Green Farmers	PRICE SENSITIVE	13/12/23	261.39KB	Share
BOD	Notice to Shareholders		01/12/23	153.98KB	Share
BOD	Appointment of Voluntary Administrators	PRICE SENSITIVE	29/11/23	216.54KB	Share
BOD	Suspension from Quotation	PRICE SENSITIVE	28/11/23	115.31KB	Share
BOD	Updated Constitution		27/11/23	481.94KB	Share
BOD	Results of Meeting		27/11/23	237.22KB	Share
BOD	Trading Halt	PRICE SENSITIVE	24/11/23	121.76KB	Share
BOD	Bod receives $1.645m R&D Tax Rebate	PRICE SENSITIVE	22/11/23	273.06KB	Share
BOD	Capital Raise Update	PRICE SENSITIVE	21/11/23	239.02KB	Share
BOD	Capital Raise Update		15/11/23	249.73KB	Share
BOD	Proposed issue of securities - BOD		08/11/23	24.41KB	Share
BOD	Proposed issue of securities - BOD		08/11/23	24.6KB	Share
BOD	Investor Presentation	PRICE SENSITIVE	08/11/23	7.43MB	Share
BOD	Reinstatement to Official Quotation	PRICE SENSITIVE	08/11/23	87.21KB	Share
BOD	Bod Science announces placement to raise A$2m	PRICE SENSITIVE	08/11/23	295.39KB	Share
BOD	Extension of Voluntary Suspension		06/11/23	32.34KB	Share
BOD	Continuation of Suspension from Quotation	PRICE SENSITIVE	02/11/23	118.22KB	Share
BOD	Suspension from Quotation	PRICE SENSITIVE	01/11/23	92.18KB	Share
BOD	Appendix 4G and Corporate Governance Statement		01/11/23	877.43KB	Share
BOD	Annual Report		01/11/23	3.03MB	Share
BOD	Appendix 4C	PRICE SENSITIVE	31/10/23	214.08KB	Share
BOD	Quarterly Activities Report	PRICE SENSITIVE	31/10/23	289.58KB	Share
BOD	Grant of ASX waiver regarding Aqua Phase acquisition		30/10/23	132KB	Share
BOD	Notice of Annual General Meeting/Proxy Form		26/10/23	651.97KB	Share
BOD	Application for quotation of securities - BOD		06/10/23	24.81KB	Share
BOD	Notification regarding unquoted securities - BOD		06/10/23	23.66KB	Share
BOD	Issue of Equity		06/10/23	567.85KB	Share
BOD	Results of Meeting		03/10/23	235.53KB	Share
BOD	Date of AGM		02/10/23	171.54KB	Share
BOD	Aqua Phase CBD PK Study Results	PRICE SENSITIVE	27/09/23	277.83KB	Share
BOD	Schedule 3 CBD trial preliminary results	PRICE SENSITIVE	06/09/23	307.9KB	Share
BOD	Trading Halt	PRICE SENSITIVE	04/09/23	121.72KB	Share
BOD	Notice of Extraordinary General Meeting		31/08/23	717.44KB	Share
BOD	FY23 Appendix 4E and Financial Statements	PRICE SENSITIVE	30/08/23	950.21KB	Share
BOD	Ceasing to be a substantial holder		23/08/23	622.9KB	Share
BOD	Cancellation of Securities		23/08/23	1.17MB	Share
BOD	Rectification of Appendix 2A		23/08/23	1.15MB	Share
BOD	Notification of cessation of securities - BOD		23/08/23	23.76KB	Share
BOD	Notification regarding unquoted securities - BOD		22/08/23	23.9KB	Share
BOD	Application for quotation of securities - BOD		22/08/23	24.91KB	Share
BOD	Cleansing Notice		22/08/23	239.5KB	Share
BOD	Change of Principal Place of Business		14/08/23	174.84KB	Share
BOD	Notification regarding unquoted securities - BOD		11/08/23	25.53KB	Share
BOD	Application for quotation of securities - BOD		11/08/23	24.97KB	Share
BOD	Cleansing Notice		11/08/23	273.58KB	Share
BOD	Bod completes acquisition of Aqua Phase	PRICE SENSITIVE	10/08/23	283.17KB	Share
BOD	Proposed issue of securities - BOD		03/08/23	33.5KB	Share
BOD	Capital Raising Investor Presentation	PRICE SENSITIVE	03/08/23	8.01MB	Share
BOD	Bod announces placement to raise $1.9m	PRICE SENSITIVE	03/08/23	285.66KB	Share
BOD	Trading Halt	PRICE SENSITIVE	01/08/23	116.68KB	Share
BOD	Appendix 4C	PRICE SENSITIVE	31/07/23	1.07MB	Share
BOD	Quarterly Activities Report	PRICE SENSITIVE	31/07/23	372.76KB	Share
BOD	Completion of Pivotal Aqua Phase PK Studies	PRICE SENSITIVE	25/07/23	238.91KB	Share
BOD	Investor Presentation		13/07/23	6.7MB	Share
BOD	Webinar Invitation		12/07/23	262.21KB	Share
BOD	Phase IIB Clinical Trial of Schedule 3	PRICE SENSITIVE	10/07/23	225.29KB	Share
BOD	Updates on Phase IIB clinical trial of Schedule 3 CBD	PRICE SENSITIVE	03/07/23	231.83KB	Share
BOD	Bod announces progress in Aqua Phase PK Studies	PRICE SENSITIVE	30/06/23	304.64KB	Share
BOD	BOD and Malaysian Antah Group sign Letter of Intent	PRICE SENSITIVE	21/06/23	335.93KB	Share
BOD	Updates regarding Aqua Phase Delivery Technology	PRICE SENSITIVE	23/05/23	228.88KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/04/23	691.75KB	Share
BOD	Change in Chairman's role		24/04/23	173.91KB	Share
BOD	Bod completes recruitment of Phase IIb clinical trial		04/04/23	231.49KB	Share
BOD	Aqua Phase PK Study submitted for ethics approval		28/03/23	224.7KB	Share
BOD	BOD reaches milestone in Schedule 3 CBD clinical trial		13/03/23	241.49KB	Share
BOD	Change of Director's Interest Notice - David Baker		10/03/23	166.95KB	Share
BOD	Grant of ASX Waiver		08/03/23	333.8KB	Share
BOD	Update on acquisition of Aqua Phase	PRICE SENSITIVE	07/03/23	219.71KB	Share
BOD	Bod Science establishes R&D funding facility	PRICE SENSITIVE	06/03/23	200.35KB	Share
BOD	Appendix 4D and Half Year Account	PRICE SENSITIVE	24/02/23	1004.31KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/01/23	707.44KB	Share
BOD	Appointment of Company Secretary		24/01/23	170.87KB	Share
BOD	Notification of cessation of securities - BOD		23/01/23	21.59KB	Share
BOD	Bod Science receives $1.512 million R&D tax rebate	PRICE SENSITIVE	20/12/22	212.3KB	Share
BOD	Change of Director's Interest Notice - G Livery and A Bedi		19/12/22	465.04KB	Share
BOD	Notification of cessation of securities - BOD		19/12/22	21.53KB	Share
BOD	Change of Company Name to Bod Science Limited		12/12/22	160.51KB	Share
BOD	Appendix 3Y's - Baker, Livery, Patterson and Bedi		06/12/22	583.89KB	Share
BOD	Secton 708A cleansing notice		06/12/22	78.94KB	Share
BOD	Application for quotation of securities - BOD		06/12/22	24.72KB	Share
BOD	Bod secures licensing and supply agreement with Arrotex	PRICE SENSITIVE	02/12/22	272.81KB	Share
BOD	Notification regarding unquoted securities - BOD		02/12/22	26.8KB	Share
BOD	Notification regarding unquoted securities - BOD		02/12/22	29.49KB	Share
BOD	Results of Annual General Meeting		28/11/22	249.2KB	Share
BOD	Chief Executive Officer presentation to the 2022 AGM		28/11/22	832.93KB	Share
BOD	Bod Softgel offers outstanding bioavailability	PRICE SENSITIVE	22/11/22	239.09KB	Share
BOD	Final Director's Interest Notice		09/11/22	193.01KB	Share
BOD	Resignation of Director		09/11/22	164.37KB	Share
BOD	Annual Report to shareholders		28/10/22	4.24MB	Share

BOD Further delay in lodgement of App 4D and Half Year Report
29/04/24		234.8KB	Share
BOD Entry into Deed of Company Arrangement
26/04/24	PRICE SENSITIVE	240.67KB	Share
BOD Quarterly Activities Report / Appendix 4C
24/04/24	PRICE SENSITIVE	1.17MB	Share
BOD Change of Principal Place of Business
12/04/24		229.58KB	Share
BOD Convening of Second Meeting of Creditors
28/03/24		321.53KB	Share
BOD Further delay in lodgement of App.4D and Half Year Report
25/03/24		271.77KB	Share
BOD Delay in lodgement of Appendix 4D and Half Year Report
29/02/24		271.9KB	Share
BOD Change of Director's Interest Notice
08/02/24		126.58KB	Share
BOD Notification of cessation of securities - BOD
08/02/24		12.73KB	Share
BOD Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	643.56KB	Share
BOD Extension of Convening Period for 2nd Meeting of Creditors
15/12/23	PRICE SENSITIVE	587.14KB	Share
BOD Medicinal cannabis supply agreement with Green Farmers
13/12/23	PRICE SENSITIVE	261.39KB	Share
BOD Notice to Shareholders
01/12/23		153.98KB	Share
BOD Appointment of Voluntary Administrators
29/11/23	PRICE SENSITIVE	216.54KB	Share
BOD Suspension from Quotation
28/11/23	PRICE SENSITIVE	115.31KB	Share
BOD Updated Constitution
27/11/23		481.94KB	Share
BOD Results of Meeting
27/11/23		237.22KB	Share
BOD Trading Halt
24/11/23	PRICE SENSITIVE	121.76KB	Share
BOD Bod receives $1.645m R&D Tax Rebate
22/11/23	PRICE SENSITIVE	273.06KB	Share
BOD Capital Raise Update
21/11/23	PRICE SENSITIVE	239.02KB	Share
BOD Capital Raise Update
15/11/23		249.73KB	Share
BOD Proposed issue of securities - BOD
08/11/23		24.41KB	Share
BOD Proposed issue of securities - BOD
08/11/23		24.6KB	Share
BOD Investor Presentation
08/11/23	PRICE SENSITIVE	7.43MB	Share
BOD Reinstatement to Official Quotation
08/11/23	PRICE SENSITIVE	87.21KB	Share
BOD Bod Science announces placement to raise A$2m
08/11/23	PRICE SENSITIVE	295.39KB	Share
BOD Extension of Voluntary Suspension
06/11/23		32.34KB	Share
BOD Continuation of Suspension from Quotation
02/11/23	PRICE SENSITIVE	118.22KB	Share
BOD Suspension from Quotation
01/11/23	PRICE SENSITIVE	92.18KB	Share
BOD Appendix 4G and Corporate Governance Statement
01/11/23		877.43KB	Share
BOD Annual Report
01/11/23		3.03MB	Share
BOD Appendix 4C
31/10/23	PRICE SENSITIVE	214.08KB	Share
BOD Quarterly Activities Report
31/10/23	PRICE SENSITIVE	289.58KB	Share
BOD Grant of ASX waiver regarding Aqua Phase acquisition
30/10/23		132KB	Share
BOD Notice of Annual General Meeting/Proxy Form
26/10/23		651.97KB	Share
BOD Application for quotation of securities - BOD
06/10/23		24.81KB	Share
BOD Notification regarding unquoted securities - BOD
06/10/23		23.66KB	Share
BOD Issue of Equity
06/10/23		567.85KB	Share
BOD Results of Meeting
03/10/23		235.53KB	Share
BOD Date of AGM
02/10/23		171.54KB	Share
BOD Aqua Phase CBD PK Study Results
27/09/23	PRICE SENSITIVE	277.83KB	Share
BOD Schedule 3 CBD trial preliminary results
06/09/23	PRICE SENSITIVE	307.9KB	Share
BOD Trading Halt
04/09/23	PRICE SENSITIVE	121.72KB	Share
BOD Notice of Extraordinary General Meeting
31/08/23		717.44KB	Share
BOD FY23 Appendix 4E and Financial Statements
30/08/23	PRICE SENSITIVE	950.21KB	Share
BOD Ceasing to be a substantial holder
23/08/23		622.9KB	Share
BOD Cancellation of Securities
23/08/23		1.17MB	Share
BOD Rectification of Appendix 2A
23/08/23		1.15MB	Share
BOD Notification of cessation of securities - BOD
23/08/23		23.76KB	Share
BOD Notification regarding unquoted securities - BOD
22/08/23		23.9KB	Share
BOD Application for quotation of securities - BOD
22/08/23		24.91KB	Share
BOD Cleansing Notice
22/08/23		239.5KB	Share
BOD Change of Principal Place of Business
14/08/23		174.84KB	Share
BOD Notification regarding unquoted securities - BOD
11/08/23		25.53KB	Share
BOD Application for quotation of securities - BOD
11/08/23		24.97KB	Share
BOD Cleansing Notice
11/08/23		273.58KB	Share
BOD Bod completes acquisition of Aqua Phase
10/08/23	PRICE SENSITIVE	283.17KB	Share
BOD Proposed issue of securities - BOD
03/08/23		33.5KB	Share
BOD Capital Raising Investor Presentation
03/08/23	PRICE SENSITIVE	8.01MB	Share
BOD Bod announces placement to raise $1.9m
03/08/23	PRICE SENSITIVE	285.66KB	Share
BOD Trading Halt
01/08/23	PRICE SENSITIVE	116.68KB	Share
BOD Appendix 4C
31/07/23	PRICE SENSITIVE	1.07MB	Share
BOD Quarterly Activities Report
31/07/23	PRICE SENSITIVE	372.76KB	Share
BOD Completion of Pivotal Aqua Phase PK Studies
25/07/23	PRICE SENSITIVE	238.91KB	Share
BOD Investor Presentation
13/07/23		6.7MB	Share
BOD Webinar Invitation
12/07/23		262.21KB	Share
BOD Phase IIB Clinical Trial of Schedule 3
10/07/23	PRICE SENSITIVE	225.29KB	Share
BOD Updates on Phase IIB clinical trial of Schedule 3 CBD
03/07/23	PRICE SENSITIVE	231.83KB	Share
BOD Bod announces progress in Aqua Phase PK Studies
30/06/23	PRICE SENSITIVE	304.64KB	Share
BOD BOD and Malaysian Antah Group sign Letter of Intent
21/06/23	PRICE SENSITIVE	335.93KB	Share
BOD Updates regarding Aqua Phase Delivery Technology
23/05/23	PRICE SENSITIVE	228.88KB	Share
BOD Quarterly Activities Report and Appendix 4C
28/04/23	PRICE SENSITIVE	691.75KB	Share
BOD Change in Chairman's role
24/04/23		173.91KB	Share
BOD Bod completes recruitment of Phase IIb clinical trial
04/04/23		231.49KB	Share
BOD Aqua Phase PK Study submitted for ethics approval
28/03/23		224.7KB	Share
BOD BOD reaches milestone in Schedule 3 CBD clinical trial
13/03/23		241.49KB	Share
BOD Change of Director's Interest Notice - David Baker
10/03/23		166.95KB	Share
BOD Grant of ASX Waiver
08/03/23		333.8KB	Share
BOD Update on acquisition of Aqua Phase
07/03/23	PRICE SENSITIVE	219.71KB	Share
BOD Bod Science establishes R&D funding facility
06/03/23	PRICE SENSITIVE	200.35KB	Share
BOD Appendix 4D and Half Year Account
24/02/23	PRICE SENSITIVE	1004.31KB	Share
BOD Quarterly Activities Report and Appendix 4C
31/01/23	PRICE SENSITIVE	707.44KB	Share
BOD Appointment of Company Secretary
24/01/23		170.87KB	Share
BOD Notification of cessation of securities - BOD
23/01/23		21.59KB	Share
BOD Bod Science receives $1.512 million R&D tax rebate
20/12/22	PRICE SENSITIVE	212.3KB	Share
BOD Change of Director's Interest Notice - G Livery and A Bedi
19/12/22		465.04KB	Share
BOD Notification of cessation of securities - BOD
19/12/22		21.53KB	Share
BOD Change of Company Name to Bod Science Limited
12/12/22		160.51KB	Share
BOD Appendix 3Y's - Baker, Livery, Patterson and Bedi
06/12/22		583.89KB	Share
BOD Secton 708A cleansing notice
06/12/22		78.94KB	Share
BOD Application for quotation of securities - BOD
06/12/22		24.72KB	Share
BOD Bod secures licensing and supply agreement with Arrotex
02/12/22	PRICE SENSITIVE	272.81KB	Share
BOD Notification regarding unquoted securities - BOD
02/12/22		26.8KB	Share
BOD Notification regarding unquoted securities - BOD
02/12/22		29.49KB	Share
BOD Results of Annual General Meeting
28/11/22		249.2KB	Share
BOD Chief Executive Officer presentation to the 2022 AGM
28/11/22		832.93KB	Share
BOD Bod Softgel offers outstanding bioavailability
22/11/22	PRICE SENSITIVE	239.09KB	Share
BOD Final Director's Interest Notice
09/11/22		193.01KB	Share
BOD Resignation of Director
09/11/22		164.37KB	Share
BOD Annual Report to shareholders
28/10/22		4.24MB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 2.4¢		Change 0.000(0.00%)		Mkt cap ! $4.256M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

BOD (ASX) Chart

Day chart unavailable

BOD SCIENCE LIMITED - Announcements

Announcements

Top Stories